Eureka Therapeutics, Inc.

Memorial Sloan Kettering Cancer Center

Javier Morales

Hong Liu

Yiyang Xu

Pengbo Zhang

Lianxing Liu

Yoko Nakano

Zhiyuan Yang

Jingyi Xiang

Lucas Horan

David Spriggs

Hongruo Yun

Timothy M Acker

Guangyan Xiong

Shan Li

Yixiang Xu

Shaohua Xu

Jun Cui

Xiaomei Ge

Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression.

Antibodies to mucin-16 (MUC16), encoding polynucleotides and methods of treating MUC16-positive cancer

Described herein are antibodies (e.g., single chain variable fragment (scFv) antibodies) and constructs comprising antibody moieties that bind to the extracellular domain of CD22 or a portion thereof (e.g., SEQ ID NO: 205 or a portion thereof). Also provided herein are methods of using the same or compositions thereof for the therapeutic treatment of diseases characterized by CD22 expression, in particular, B-cell lymphomas and leukemias.

Constructs trageting CD22 and uses thereof

The present application provides chimeric antibody-TCR constructs comprising an antigen-binding module that specifically binds to a target antigen and a T cell receptor module capable of recruiting at least one TCR-associated signaling molecule. Also provided are methods of making and using these constructs.

Chimeric antibody/T-cell receptor constructs and uses thereof

The present application provides constructs comprising an antibody moiety specifically recognizing Glypican 3 (GPC3), such as a cell surface-bound GPC3. Also provided are methods of making and using these constructs.

Constructs specifically recognizing glypican 3 and uses thereof

Growing community of inventors

San Jose, CA, United States of America

Javier Morales